Azeliragon HCl

Description: Azeliragon is a potent and orally active inhibitor of RAGE (receptor for advanced glycation endproducts), a pattern recognition receptor, which affects the movement of amyloid, an Alzheimer's-associated protein, into the brain. Target: Others. Smiles: ClC1=CC=C(C=C1)OC2=CC=C(N3C=C(C4=CC=C(OCCCN(CC)CC)C=C4)N=C3CCCC)C=C2.Cl.Cl. References: Panza F, Seripa D, Solfrizzi V, Imbimbo BP, Lozupone M, Leo A, Sardone R, Gagliardi G, Lofano L, Creanza BC, Bisceglia P, Daniele A, Bellomo A, Greco A, Logroscino G. Emerging drugs to reduce abnormal beta-amyloid protein in Alzheimer's disease patients. Expert Opin Emerg Drugs. 2016 Dec,21(4):377-391. Epub 2016 Oct 6. Review. PubMed PMID: 27678025.